Fateeha Furqan, MD, Medical College of Wisconsin, Milwaukee, WI, highlights the role of novel non-covalent BTK inhibitors (BTKi), such as pirtobrutinib, in the treatment of non-Hodgkin lymphoma (NHL). Non-covalent BTKis are generally well tolerated and effective and, therefore, do not require a high degree of monitoring upon administration. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть